视网膜母细胞瘤幸存者继发性骨肉瘤的临床表现是否不同于传统骨肉瘤,我们如何发现它们?
本研究回顾性分析2000年2月至2019年12月治疗的540例视网膜母细胞瘤患者,其中12例发生四肢继发性骨肉瘤(共14个肿瘤)。所有患者按医院政策每年接受锝-99m骨扫描监测,并按传统骨肉瘤策略治疗。5年总生存率为86%(95%CI 68%至100%),骨扫描在所有14个肿瘤中均显示摄取增高,作者认为至少每年临床评估和骨扫描可能有助于早期发现。
要点
- 视网膜母细胞瘤治疗后每年骨扫描监测,14个继发性骨肉瘤均显示摄取增高。
- 9/14个肿瘤位于骨干,5个位于干骺端,股骨最常见(10个),其次胫骨(4个)。
- 5年总生存率为86%(95%CI 68%至100%),无局部复发。
核心结论
- 视网膜母细胞瘤治疗后存活的继发性骨肉瘤似乎略偏好长骨骨干,但原因不明。
- 继发性骨肉瘤的临床生存期可能不劣于传统骨肉瘤。
- 至少每年临床评估和骨扫描或其他影像学检查的密切随访似乎有助于检测视网膜母细胞瘤治疗后的继发性骨肉瘤。
- 需要更大规模的多机构研究来证实这些观察结果。
研究设计与样本
- 回顾性研究,2000年2月至2019年12月治疗540例视网膜母细胞瘤患者,其中12例(6男6女)发生四肢继发性骨肉瘤,共14个肿瘤(10个股骨,4个胫骨)。
- 所有患者按本院政策每年接受锝-99m骨扫描监测,并按新辅助化疗、广泛切除和辅助化疗的相同策略治疗。
- 中位随访12年(范围8至21年),骨肉瘤诊断中位年龄9岁(范围5至15岁),从视网膜母细胞瘤诊断到骨肉瘤诊断的中位间隔8年(范围5至15年)。
- 通过X线平片和MRI评估影像学特征,通过病历回顾评估临床特征,评估总生存、局部无复发生存和无转移生存。
- 证据等级为IV级,治疗性研究。
主要发现
- 14个肿瘤中9个以骨干为中心,5个位于干骺端;股骨最常见(10个),其次胫骨(4个)。
- 中位肿瘤大小9 cm(范围5至13 cm)。
- 骨肉瘤手术切除后无局部复发,骨肉瘤诊断后5年总生存率为86%(95%CI 68%至100%)。
- 所有14个肿瘤的锝骨扫描均显示病灶摄取增高。
- 14个肿瘤中10个因患者主诉患肢疼痛而在临床检查中发现,4例无临床症状者通过骨扫描异常摄取发现。
关键数值与推荐
- 5年总生存率为86%(95%CI 68%至100%)。
- 中位肿瘤大小9 cm(范围5至13 cm)。
- 14个肿瘤中9个位于骨干,5个位于干骺端。
临床怎么用
- 本研究中心的做法是按医院政策对所有视网膜母细胞瘤治疗后患者每年进行锝-99m骨扫描监测。
- 作者认为至少每年临床评估和骨扫描或其他影像学检查的密切随访似乎有助于检测视网膜母细胞瘤治疗后的继发性骨肉瘤。
局限性
- 需要更大规模的多机构研究来证实这些观察结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteosarcoma is the most common secondary malignancy among survivors of retinoblastoma. Most previous reports on secondary malignancy of retinoblastoma included all types of secondary malignancies without a focus on osteosarcoma, owing to its rarity. In addition, there are few studies suggesting tools for regular surveillance for early detection. QUESTIONS/PURPOSES: (1) What are the radiologic and clinical characteristics of secondary osteosarcoma after retinoblastoma? (2) What is the clinical survivorship? (3) Is a radionuclide bone scan a reasonable imaging modality for early detection in patients with retinoblastoma? METHODS: Between February 2000 and December 2019, we treated 540 patients for retinoblastoma. Twelve patients (six male, six female) subsequently developed an osteosarcoma in the extremities; two of these patients had two sites of osteosarcoma (10 femurs, four tibiae) . A Technetium-99m bone scan image was examined annually in all patients for regular surveillance after the treatment of retinoblastoma as per our hospital's policy. All patients were treated with the same strategy as that used for primary conventional osteosarcoma, namely neoadjuvant chemotherapy, wide excision, and adjuvant chemotherapy. The median follow-up period was 12 years (range 8 to 21 years). The median age at the time of diagnosis of osteosarcoma was 9 years (range 5 to 15 years), and the median interval from retinoblastoma diagnosis to osteosarcoma diagnosis was 8 years (range 5 to 15 years). Radiologic characteristics were assessed with plain radiographs and MRI, while clinical characteristics were assessed through a retrospective review of medical records. For clinical survivorship, we evaluated overall survival, local recurrence-free survival, and metastasis-free survival. We reviewed the results of bone scans and clinical symptoms at the time of diagnosis for osteosarcoma after retinoblastoma. RESULTS: In nine of 14 patients, the tumor had a diaphyseal center, and five of the tumors were located at the metaphysis. The femur was the most common site (n = 10), followed by the tibia (n = 4). The median tumor size was 9 cm (range 5 to 13 cm). There was no local recurrence after surgical resection of the osteosarcoma, and the 5-year overall survival rate after the diagnosis of osteosarcoma was 86% (95% CI 68% to 100%). In all 14 tumors, the Technetium bone scan showed increased uptake in the lesions. Ten of 14 tumors were examined in clinic because of patient complaints of pain in the affected limb. Four patients showed no clinical symptoms detected by abnormal uptake on bone scan. CONCLUSION: For unclear reasons, secondary osteosarcomas in patients who were alive after the treatment of retinoblastoma had a slight predilection for the diaphysis of the long bone compared with patients with spontaneous osteosarcoma in other reports. The clinical survivorship of osteosarcoma as a secondary malignancy after retinoblastoma may not be inferior to that of conventional osteosarcoma. Close follow-up with at least yearly clinical assessment and bone scans or other imaging modalities appears to be helpful in detecting secondary osteosarcoma after the treatment of patients with retinoblastoma. Larger multi-institutional studies will be needed to substantiate these observations.Level of Evidenc e Level IV, therapeutic study.
引用
- Kim Y, Park JW, Cho HS, et al. Does the Clinical Presentation of Secondary Osteosarcoma in Patients Who Survive Retinoblastoma Differ From That of Conventional Osteosarcoma and How Do We Detect Them? Clin Orthop Relat Res. 2023. PMID: 37145140. doi:10.1097/CORR.0000000000002667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。